Second allogeneic stem cell transplantation in myeloid malignancies

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Relapse after allogeneic stem cell transplantation (allo-SCT) for myeloid malignancies presents a significant challenge.
• A second allo-SCT is a potential salvage option for these patients.

Purpose of the Study:

• To retrospectively analyze the outcomes of a second allo-SCT in patients with relapsed myeloid malignancies.
• To evaluate the efficacy and safety of second allo-SCT in this patient population.

Main Methods:

• Retrospective analysis of 25 patients with myeloid malignancies (acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis) who received a second allo-SCT after relapse.
• Assessment of pre-transplant remission status, conditioning strategies, remission rates, relapse, survival, and treatment-related mortality.

Main Results:

• Complete remission was achieved in all evaluable patients post-second allo-SCT (21/21).
• Relapse occurred in 44% (11/25) of patients.
• Overall survival was 32% (8/25) at a median follow-up of 18 months, with 24% (6/25) in stable remission.
• Treatment-related mortality was 32% (8/25).

Conclusions:

• Second allo-SCT can lead to stable remission in some patients with relapsed myeloid malignancies.
• High rates of relapse and treatment-related mortality remain significant challenges.
• Further optimization of conditioning regimens, immunosuppression, and post-transplant surveillance is crucial for improving outcomes.